Figure 2 | Scientific Reports

Figure 2

From: HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice

Figure 2

Antiviral efficacy of HA1077 in an orthotopic xenograft mouse model of HCV replication. (a) Serum HCV RNA titer in NOD-SCID mice carrying HCV-infected Huh7 cells implanted in the liver. The mice were given saline or HA1077 (100 mg/kg body weight) perorally twice a day for 15 days. (b,c) Immunostaining of HCV core protein (Core) in the xenografts retrieved at day 15 from the three randomly picked mice receiving HA1077 [#1, 2, and 3 marked in (a)] or the control mouse receiving saline (b). Quantification of Core-positive cells using the ImageJ program (c). Ctrl, sample from saline-receiving mice. Scale bars, 100 μm. In all panels, data are mean ± s.d. **P < 0.01 by unpaired two-tailed Student’s t-test.

Back to article page